This comparative effectiveness study examines whether differential censoring could explain the inconsistent results in trials investigating the addition of programmed cell death 1 protein/programmed cell death 1 ligand 1 inhibitors to platinum-based chemotherapy for advanced urothelial carcinoma.
This cohort study examines the potential curative clinical outcomes of adding serial circulating tumor DNA assays to standard-of-care imaging surveillance in patients with resected colorectal…
Tens of thousands of Germans have protested in Berlin and other cities against the rise of the far-right, anti-immigrant Alternative for Germany party ahead of…
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor…
PURPOSEMAP2K1/MEK1 mutations are potentially actionable drivers in cancer. MAP2K1 mutations have been functionally classified into three groups according to their dependency on upstream RAS/RAF signaling.…
Robert F. Kennedy Jr. is still a radical left lunatic who is anti-energy, a “big time” taxer and completely incoherent about our nation’s health.
This secondary analysis of a parallel-design double-blind secondary stroke prevention trial in patients with cryptogenic stroke and atrial cardiopathy evaluates the association between apixaban and…
This cohort study analyzes electroencephalography data from healthy participants to analyze and validate a cortical biomarker signature for pain, which comprised the measures sensorimotor peak…
AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic hormone receptor…
Nature Methods – Spatial-Mux-seq adds to a growing portfolio of innovative spatial omics technologies and enables simultaneous profiling of up to five omic modalities in…
Results from the DESTINY-Breast06 trial led to the approval of T-DXd for patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer.
